Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Edward Nash maintains a 'Buy' rating on Corcept Therapeutics (NASDAQ:CORT) and raises the price target from $34 to $35.
August 25, 2023 | 2:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity maintains a 'Buy' rating on Corcept Therapeutics and raises the price target from $34 to $35.
The news of Canaccord Genuity maintaining a 'Buy' rating and raising the price target for Corcept Therapeutics is likely to instill confidence in investors and could potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100